Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | EPOR | P19235 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28428910 | 0.84 | CA1 (0.52) | SMN1; SMN2LMNACA1CA2HTT | |
| SCHEMBL16995567 | 0.81 | LMNA (0.52) | SMN1; SMN2LMNACA1CA2L3MBTL1 | |
| SCHEMBL16995783 | 0.81 | LMNA (0.52) | SMN1; SMN2LMNACA1CA2L3MBTL1 | |
| SCHEMBL24038747 | 0.81 | LMNA (0.76) | SMN1; SMN2LMNAEPORHTTL3MBTL1 | |
| SCHEMBL15516041 | 0.80 | LMNA (0.56) | SMN1; SMN2LMNACA1CA2HTT | |
| SCHEMBL28421181 | 0.80 | CA1 (0.50) | SMN1; SMN2LMNACA1CA2HTT | |
| SCHEMBL23451303 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAEPORHTTL3MBTL1 | |
| SCHEMBL31376899 | 0.79 | LMNA (0.57) | SMN1; SMN2LMNAEPORHTTL3MBTL1 | |
| SCHEMBL30101194 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAEPORHTTL3MBTL1 | |
| SCHEMBL25933063 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAEPORHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359392-B2 | Dendrimer scaffolds for pharmaceutical use | VICTORIA LINK LIMITED (NZ) | 2016-06-07 | — | — | US | disclosed |
| US-20160145287-A2 | Dendrimer Scaffolds for Pharmaceutical Use | VICTORIA LINK LIMITED (NZ) | 2016-05-26 | — | — | US | disclosed |
| US-20150225439-A1 | Dendrimer Scaffolds for Pharmaceutical Use | VICTORIA LINK LTD (NZ) | 2015-08-13 | — | — | US | disclosed |
| WO-2014038963-A9 | DENDRIMER SCAFFOLDS FOR PHARMACEUTICAL USE | VICTORIA LINK LIMITED (NZ) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014038963-A1 | DENDRIMER SCAFFOLDS FOR PHARMACEUTICAL USE | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225439-A1 | Dendrimer Scaffolds for Pharmaceutical Use | CD38, ADCYAP1R1, PIGO | SMN1; SMN2 3345/4885LMNA 2112/4885CA1 4287/4885 |
| US-20160145287-A2 | Dendrimer Scaffolds for Pharmaceutical Use | CD38, ADCYAP1R1, PIGO | SMN1; SMN2 3345/4885LMNA 2112/4885CA1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.